Aspen Neuroscience, Inc. filed a Form 8-A12B on October 29, 2026, to register its Common Stock, $0.0001 par value per share, on the Nasdaq Global Select Market under Section 12(b) of the Securities Exchange Act of 1934.

Key Highlights

  • Security registered: Common Stock, $0.0001 par value per share, of Aspen Neuroscience, Inc.
  • Exchange: NASDAQ:ASPE listed on the Nasdaq Global Select Market.
  • Related registration statement: Form S-1 filed under File No. 333-299393, initially filed October 9, 2026, and amended October 22, 2026 and October 26, 2026.
  • Incorporation by reference: The description of capital stock is incorporated from the "Description of Capital Stock" section of the Form S-1 prospectus.
  • No Section 12(g) registration: The filing states that no securities are being registered pursuant to Section 12(g) of the Exchange Act.
  • Signed by: Damien McDevitt, Ph.D., President and Chief Executive Officer, dated October 29, 2026.

Aspen Neuroscience Registers Common Stock for Nasdaq Listing via Form 8-A

According to the filing, Aspen Neuroscience, Inc., a Delaware corporation with its principal offices at 10835 Road to the Cure, Suite 100, San Diego, CA 92121-1123, submitted a Form 8-A12B to register its Common Stock, $0.0001 par value per share, on the Nasdaq Global Select Market. The registration is effective pursuant to Section 12(b) of the Securities Exchange Act of 1934, as indicated by the checked box on the form.

The filing incorporates by reference the description of the Common Stock contained under the heading "Description of Capital Stock" in the prospectus included in the registrant's Registration Statement on Form S-1 (File No. 333-299393). That Form S-1 was initially filed with the Securities and Exchange Commission on October 9, 2026, and subsequently amended on October 22, 2026 and October 26, 2026. The filing further states that any prospectus subsequently filed pursuant to Rule 424(b) under the Securities Act of 1933 shall be deemed incorporated by reference.

Regarding exhibits, the filing states that no exhibits are required because no other securities of the registrant are registered on The Nasdaq Stock Market LLC and the securities are not being registered under Section 12(g). The form was signed by Damien McDevitt, Ph.D., in his capacity as President and Chief Executive Officer, on October 29, 2026.

What Was Disclosed

Aspen Neuroscience, Inc. registered its Common Stock, $0.0001 par value per share, on the Nasdaq Global Select Market via a Form 8-A12B filed October 29, 2026, incorporating the capital stock description from its Form S-1 (File No. 333-299393).